Evidence map›Paper›PMID 28403154›Full record

Trial reportPloS one2017

Effect of transdermal magnesium cream on serum and urinary magnesium levels in humans: A pilot study.

Lindsy Kass, Andrea Rosanoff, Amy Tanner, Keith Sullivan, William McAuley, Michael Plesset

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Physiology of a Forgotten Electrolyte-Magnesium Disorders.Advances in kidney disease and health · 2023
    Review
  3. How to manage a high-output stoma.Frontline gastroenterology · 2022
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lindsy KassUniversity of Hertfordshire, Hatfield, Hertfordshire, United Kingdom.ORCID http://orcid.org/0000-0003-2079-4584
Andrea RosanoffCenter for Magnesium Education & Research, Pahoa, Hawaii, United States of America.
Amy TannerUniversity of Hertfordshire, Hatfield, Hertfordshire, United Kingdom.
Keith SullivanUniversity of Hertfordshire, Hatfield, Hertfordshire, United Kingdom.
William McAuleyUniversity of Hertfordshire, Hatfield, Hertfordshire, United Kingdom.
Michael PlessetCenter for Magnesium Education & Research, Pahoa, Hawaii, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral magnesium supplementation is commonly used to support a low magnesium diet. This investigation set out to determine whether magnesium in a cream could be absorbed transdermally in humans to improve magnesium status. METHODS AND

findingsIn this single blind, parallel designed pilot study, n = 25 participants (aged 34.3+/-14.8y, height 171.5+/-11cm, weight 75.9 +/-14 Kg) were randomly assigned to either a 56mg/day magnesium cream or placebo cream group for two weeks. Magnesium serum and 24hour urinary excretion were measured at baseline and at 14 days intervention. Food diaries were recorded for 8 days during this period. Mg test and placebo groups' serum and urinary Mg did not differ at baseline. After the Mg2+ cream intervention there was a clinically relevant increase in serum magnesium (0.82 to 0.89 mmol/l,p = 0.29) that was not seen in the placebo group (0.77 to 0.79 mmol/L), but was only statistically significant (p = 0.02)) in a subgroup of non-athletes. Magnesium urinary excretion increased from baseline slightly in the Mg2+ group but with no statistical significance (p = 0.48). The Mg2+ group showed an 8.54% increase in serum Mg2+ and a 9.1% increase in urinary Mg2+ while these figures for the placebo group were smaller, i.e. +2.6% for serum Mg2+ and -32% for urinary Mg2+. In the placebo group, both serum and urine concentrations showed no statistically significant change after the application of the placebo cream.

conclusionNo previous studies have looked at transdermal absorbency of Mg2+ in human subjects. In this pilot study, transdermal delivery of 56 mg Mg/day (a low dose compared with commercial transdermal Mg2+ products available) showed a larger percentage rise in both serum and urinary markers from pre to post intervention compared with subjects using the placebo cream, but statistical significance was achieved only for serum Mg2+ in a subgroup of non-athletes. Future studies should look at higher dosage of magnesium cream for longer durations.

trial registrationISRCTN registry ID No. ISRTN15136969.

Indexed as

Administration, TopicalAdultFemaleHumansMagnesiumMaleMiddle AgedPilot ProjectsSingle-Blind MethodSkin CreamYoung AdultMagnesium

Identifiers

PMID28403154
PMCPMC5389641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.